Vice President for Academic Administration
Back to the employee directory.
The Vice President for Academic Administration is the chief academic officer, collaboratively leading out in the vision, strategy, and execution of the college’s academic goals. The VPAA also assists the President and other campus leaders in establishing the overall strategic vision and strategic priorities for the college as a whole. In the absence of the President, the VPAA serves as the chief executive officer. Reporting to the VPAA are the chairs of academic divisions, the Associate Vice President for Academic Initiatives, and the directors of the Library, Records, Institutional Research, Assessment, and the Teaching Learning Center.
Postdoctoral Research, University of Missouri (2009-2010)
Field of Study: Development of gene therapy vectors for the treatment of Spinal Muscular Atrophy (SMA)
Ph.D. Microbiology, University of Missouri (2005- 2009)
Field of Study: Molecular Genetics of Spinal Muscular Atrophy (SMA)
Medical Student/Elective Research Studies, Kirksville College of Osteopathic Medicine (2002- 2005)
B.S. Biology, Union College (1997- 2002)
High School Diploma, Sunnydale Academy (1994-1997)
Rose, F.F., Meehan, P.W., Coady, T.H., Garcia, V.B., Garcia, M.L., and Lorson, C.L. (2008). The Wallerian degeneration slow (Wlds) gene does not attenuate disease in a mouse model of spinal muscular atrophy. Biochemical and Biophysical Research Communications.
Ebert, A.D., Yu, J., Rose, F.F., Mattis, V.B., Lorson, C.L., Thomson, J.A., and Svendsen, C.N. (2009). Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457, 277–280.
Rose, F.F., Mattis, V.B., Rindt, H., and Lorson, C.L. (2009). Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy. Hum. Mol. Genet. 18, 997–1005.
Butchbach, M.E.R., Rose, F.F., Jr, Rhoades, S., Marston, J., McCrone, J.T., Sinnott, R., and Lorson, C.L. (2010). Effect of diet on the survival and phenotype of a mouse model for spinal muscular atrophy. Biochem. Biophys. Res. Commun. 391, 835–840.
Glascock, J.J., Osman, E.Y., Coady, T.H., Rose, F.F., Shababi, M., and Lorson, C.L. (2011). Delivery of therapeutic agents through intracerebroventricular (ICV) and intravenous (IV) injection in mice. J Vis Exp.
Dale, J.M., Shen, H., Barry, D.M., Garcia, V.B., Rose, F.F., Lorson, C.L., and Garcia, M.L. (2011). The spinal muscular atrophy mouse model, SMAΔ7, displays altered axonal transport without global neurofilament alterations. Acta Neuropathol 122, 331–341.
Rindt, H., Buckley, D.M., Vale, S.M., Krogman, M., Rose, F.F., Jr, Garcia, M.L., and Lorson, C.L. (2012). Transgenic inactivation of murine myostatin does not decrease the severity of disease in a model of Spinal Muscular Atrophy. Neuromuscul. Disord. 22, 277–285.
Cobb, M.S., Rose, F.F., Rindt, H., Glascock, J.J., Shababi, M., Miller, M.R., Osman, E.Y., Yen, P.-F., Martin, B.R., Wetz, M.J., et al. (2013). Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy. Hum. Mol. Genet.